AstraZeneca: As bad as expected, not really worse

BUY, Fair Value  3600p (+6%)

News published on April Thursday 25, 2013
Share on

AstraZeneca reported this morning Q1 figures that were as bad as it was expected with revenues down 12% and Core EPS down 21%, in line with operating income. It is fair to say that revenues are slightly below estimates driven further down by Crestor in the US and in ROW and Seroquel as XR is also down by 16%. New products are still too small to contribute significantly but emerging markets are back to a more normal growth trend of 9% (China +21%), in line with competitors. There is no change to the guidance. Some weakness is possible although AstraZeneca was obviously not a Q1 2013 call.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities